- Clearmind Medicine (CMND, Financial) expands its clinical trial for CMND-100 with a new site at Johns Hopkins University.
- The trial for CMND-100 aims to evaluate its safety, tolerability, and potential to reduce alcohol cravings.
- This expansion marks progress in Clearmind's multinational trial efforts to address Alcohol Use Disorder (AUD).
Clearmind Medicine Inc. (CMND), a clinical-stage biotech company, has announced the expansion of its Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral treatment for Alcohol Use Disorder (AUD). The expansion includes the activation of a new clinical site at the prestigious Johns Hopkins University School of Medicine, where the first participant has been enrolled. This development follows the recent participant enrollment at Yale School of Medicine, highlighting the growing momentum in this multinational, multicenter study.
The trial is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, with a focus on identifying preliminary efficacy signals such as reductions in alcohol consumption and cravings. This expansion enhances the trial's credibility and potentially accelerates patient recruitment, as Johns Hopkins is renowned for its research capabilities.
This advancement indicates operational execution in Clearmind's development program, although it is still in early clinical stages with no definitive efficacy data available yet. The trial's progress is part of a broader effort within the psychedelic-derived therapeutics space, which aims to innovate in the treatment realms of psychiatric and addiction disorders.
